Ratings EDAP TMS S.A.

Equities

EDAP

US2683111072

Market Closed - Nasdaq Other stock markets 04:30:01 2024-05-13 pm EDT			5-day change	1st Jan Change
7.1 ^USD	0.00%		+0.28%	+34.47%

May. 13	European Equities Traded in the US as American Depositary Receipts Kick Off Week Higher	MT
May. 06	EDAP TMS S.A. Announces Positive Final Results from the HIFI Study Comparing Outcomes of Focal One®? HIFU Versus Radical Prostatectomy During Plenary Session at the 119th American Urological Association Annual Meeting	CI

Summary

Overall, the company has poor fundamentals for a medium to long-term investment strategy.
From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 48% by 2026.
Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
Analysts covering this company mostly recommend stock overweighting or purchase.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
The company has insufficient levels of profitability.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
The average consensus view of analysts covering the stock has deteriorated over the past four months.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Sector: Advanced Medical Equipment & Technology

	1st Jan change	Capi.	ESG Refinitiv
EDAP TMS S.A.	+34.47%	263M	-
THERMO FISHER SCIENTIFIC	+11.29%	225B	B
DANAHER CORPORATION	+8.76%	186B	B-
INTUITIVE SURGICAL, INC.	+12.90%	135B	B-
BOSTON SCIENTIFIC CORPORATION	+25.95%	107B	A-
SIEMENS HEALTHINEERS AG	+0.11%	63.56B	A-
EDWARDS LIFESCIENCES CORPORATION	+11.08%	51.04B	B+
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	+5.62%	51.32B	B+
AGILENT TECHNOLOGIES, INC.	+6.28%	43.3B	A
GE HEALTHCARE TECHNOLOGIES INC.	+4.80%	36.99B	-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes